Top Market Research Companies in Denmark (2026 Guide)

Denmark is a strategically distinct pharmaceutical market, with a pharmaceutical market estimated at approximately DKK 20 billion in 2026. Commercial success in Denmark depends on navigating DKMA marketing authorisation, Medicinrådet HTA recommendation, AMGROS hospital procurement, and Danish Regions collective implementation — each with distinct evidence requirements and decision-making dynamics.

Danish pharmaceutical market research in 2026 is shaped by three defining dynamics:

• Medicinrådet collective HTA: Medicinrådet (est. 2017, replacing RADS) makes independent HTA recommendations for all 5 Danish Regions collectively — unlike most European HTA bodies that advise individual payers. Companies must prepare structured benefit documentation meeting Medicinrådet evidence standards. A positive recommendation enables collective Danish Regions implementation. Market researchers must design evidence aligned to Medicinrådet's specific methodology.
• AMGROS centralised hospital procurement: AMGROS (Amgros I/S) conducts centralised hospital medicine procurement tenders on behalf of all 5 Danish Regions — negotiating prices and supply agreements for hospital-administered medicines. AMGROS tender dynamics shape hospital access and pricing for all hospital formulary medicines in Denmark. Pre-tender payer research and pricing intelligence are critical for commercial teams.
• 5-region collective implementation complexity: Denmark's 5 regions — Capital Region, Region Zealand, Region of Southern Denmark, Central Denmark Region, and North Denmark Region — collectively implement Medicinrådet recommendations while managing individual regional hospital formulary committees. Understanding regional formulary dynamics is essential for specialty medicines, oncology biologics, and rare disease products.

Danish KOL mapping requires tracking influence across a compact but clinically significant university hospital landscape. Rigshospitalet Copenhagen holds strong guideline and publication influence in oncology, haematology, cardiovascular, and transplant across all Danish regions; Aarhus University Hospital combines academic prominence with large trial enrolment volumes in oncology, cardiology, and general medicine; Odense University Hospital (OUH) leads in Region of Southern Denmark KOL access and oncology research; Herlev Hospital is a key oncology and surgery reference centre in the Capital Region; and Aalborg University Hospital provides North Denmark Region academic reach. Effective Danish KOL mapping segments influence by region, institution, therapy area, and Medicinrådet advisory involvement.

Danish payer research requires access to Medicinrådet committee members, AMGROS procurement officers, and Danish Regions formulary stakeholders — the most commercially important respondents in Danish pharmaceutical research. Payer interviews cover Medicinrådet benefit documentation preferences, AMGROS tender pricing expectations, Danish Regions collective formulary implementation dynamics, and hospital pharmacy committee decision-making. BioNixus conducts national Medicinrådet and AMGROS payer interviews as dedicated payer research programmes.

BioNixus conducts KOL mapping and payer research across Denmark in oncology, cardiovascular, immunology, rare disease, metabolic, and other specialty areas. See our Denmark pharmaceutical market research guide and top healthcare market research companies in Denmark for details.